About Index Trending news
Lists
Pricing
Syntimmune

Syntimmune

Syntimmune

Founded in 2013, Syntimmune is the worlds leader in the biology of the neonatal Fc receptor (FcRn). Syntimmune's lead program targets FcRn.

Elsewhere

Contributors to this profile

Alexa global traffic share

21 Jun 2017
$50,000,000
Venture capital (Series B)

Syntimmune Closes $50 Million Series B Financing Led by Apple Tree Partners

businesswire
+2